Covid-19 roundup: Pfiz­er rais­es 2021 vac­cine sales fore­cast to $36B; Lil­ly lands $1.3B treat­ment deal with US gov­ern­ment

Pfiz­er’s Covid-19 vac­cine in 2021 is quick­ly be­com­ing the best-sell­ing med­ical prod­uct of all time in terms of an­nu­al sales.

The com­pa­ny on Tues­day re­port­ed its quar­ter­ly earn­ings and re-upped its year­ly guid­ance on its Covid-19 vac­cine sales, say­ing the com­pa­ny an­tic­i­pates $36 bil­lion in 2021, up from its $33.5 bil­lion es­ti­mate in Ju­ly. The com­pa­ny ex­pects to de­liv­er a whop­ping 2.3 bil­lion dos­es of its vac­cine in 2021, but it ex­pects to man­u­fac­ture 3 bil­lion dos­es in to­tal by the end of De­cem­ber.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER